PEANUT trial: assessing salvage therapy for metastatic urothelial carcinoma

Presented at the first AACR Virtual Annual Meeting, the PEANUT trial is an open-label, single-arm Phase II clinical trial looking into the use of Pembrolizumab and nanoparticle albumin bound paclitaxel (nab-paclitaxel) as a possible salvage therapy for metastatic urothelial carcinoma. The trial studied 64 patients, with inclusion criteria including histological confirmation of urothelial carcinoma of the bladder or urothelium and demonstrated failure of a standard platinum-based chemotherapy treatment. The study, led by Patrizia Giannatempo and a team of researchers from Fondazione IRCCS Istituto Nazionale Tumori (Milan, Italy), San Raffaele Hospital and Scientific Institute (Milan, Italy) and Foundation Medicine (MA, USA)...